Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV001027802 | SCV000396859 | uncertain significance | Fanconi anemia complementation group P | 2018-01-12 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Labcorp Genetics |
RCV000362095 | SCV000626412 | uncertain significance | Fanconi anemia | 2022-11-01 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 894 of the SLX4 protein (p.Val894Gly). This variant is present in population databases (rs145137472, gnomAD 0.1%). This missense change has been observed in individual(s) with breast cancer and/or ovarian cancer (PMID: 22911665, 32546565). ClinVar contains an entry for this variant (Variation ID: 319164). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glycine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV000762181 | SCV000892449 | uncertain significance | not provided | 2018-07-01 | criteria provided, single submitter | clinical testing | |
Center for Genomics, |
RCV001027802 | SCV001190415 | uncertain significance | Fanconi anemia complementation group P | 2021-03-30 | criteria provided, single submitter | clinical testing | SLX4 NM_032444.3 exon 12 p.Val894Gly (c.2681T>G): This variant has not been reported in the literature and is present in 0.1% (11/10370) of Ashkenazi Jewish alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/16-3640958-A-C). This variant is present in ClinVar (Variation ID:319164). This variant amino acid Glycine (Gly) is present in multiple mammals and is not well conserved among evolutionarily distant species; this suggests that this variant may not impact the protein. Additional computational prediction tools do not suggest an impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. |
Gene |
RCV000762181 | SCV001800985 | uncertain significance | not provided | 2022-10-17 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer, as well as in healthy controls (Bakker et al., 2013; Song et al., 2021); This variant is associated with the following publications: (PMID: 22911665, 32546565) |
Institute for Clinical Genetics, |
RCV000762181 | SCV002010257 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000362095 | SCV002529309 | uncertain significance | Fanconi anemia | 2022-01-26 | criteria provided, single submitter | curation | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001194828 | SCV004241754 | uncertain significance | not specified | 2023-12-28 | criteria provided, single submitter | clinical testing | Variant summary: BTBD12 c.2681T>G (p.Val894Gly) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00033 in 282824 control chromosomes (gnomAD). c.2681T>G has been reported in the literature in individuals affected with breast cancer and/or ovarian cancer (examples: Bakker_2012, Song_2019). These report(s) do not provide unequivocal conclusions about association of the variant with Fanconi Anemia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 22911665, 36916425, 32546565). Seven submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Breakthrough Genomics, |
RCV000762181 | SCV005194167 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Leiden Open Variation Database | RCV001194828 | SCV001364633 | likely benign | not specified | 2012-08-31 | no assertion criteria provided | curation | Curator: Arleen D. Auerbach. Submitter to LOVD: Janine Bakker. |